Trials / Terminated
TerminatedNCT00456612
Radiosurgery for Glioblastoma Multiforme
Phase I/II Study of Fractionated CyberKnife Stereotactic Radiosurgery for High Grade Gliomas in Elderly Patients With Poor Performance Status
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Beth Israel Deaconess Medical Center · Academic / Other
- Sex
- All
- Age
- 66 Years
- Healthy volunteers
- Not accepted
Summary
Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly- particularly in patients who are generally in poor performance status (KPS\<70). Fractionated Cyberknife Radiosurgery can deliver equivalent doses in 5 treatments providing the same tumor control in a much shorter and tolerable schedule improving their quality of their short life. To assess the tolerability of Cyberknife Radiosurgery for High Grade Gliomas in Elderly with poor performance status. Secondary: Assessment of local control rate, progression free survival, overall survival, quality of life and toxicity and steroid dependence in this population with this regime.
Detailed description
Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly- particularly in patients who are generally in poor performance status (KPS\<70). Fractionated Cyberknife Radiosurgery can deliver equivalent doses in 5 treatments providing the same tumor control in a much shorter and tolerable schedule improving their quality of their short life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | CyberKnife | Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses. |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2007-04-05
- Last updated
- 2017-03-06
- Results posted
- 2015-10-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00456612. Inclusion in this directory is not an endorsement.